Merimac

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Merimac

What Type of Medicine is Meropenem?

Quick Facts
Active Ingredient Meropenem
Form Powder for Injection
Pharmacological Class Carbapenem Antibiotic
General Purpose Treating severe bacterial infections
Origin Synthetic

Meropenem is a powerful, synthetic antibiotic that belongs to the carbapenem pharmacological class. It is a prescription-only medicine reserved for treating serious bacterial infections. As a broad-spectrum agent, Meropenem is effective against a wider array of difficult-to-treat bacteria, including strains that may have developed resistance to older, common antibiotics.

Its critical importance in health care is recognized globally, and it is recognized as an essential medicine. This status confirms Meropenem’s vital role in combating life-threatening bacterial infections in acute settings.

Composition and Physical Form

The medicine is a single-ingredient product, with Meropenem (INN) as its sole active component. It is supplied as a sterile powder in a vial, which a healthcare professional must mix with a suitable liquid, such as sterile water or sodium chloride solution, to create an injectable solution.

Meropenem is designed exclusively for intravenous administration (injection or infusion) directly into the bloodstream by a healthcare professional. This formulation and mandatory IV route are distinctive features that underscore its intended use for serious, acute conditions where immediate, systemic action is required, unlike common oral medications.

What side effects are possible with Merimac?

Possible Side Effects and Safety Information

The safety profile of Merimac (Meropenem) is defined by officially documented adverse reactions classified by frequency and body system, as listed in regulatory documents (e.g., FDA, EMA SmPC). The information is strictly descriptive, non-advisory, and based on clinical trials and postmarketing reports.


Official Adverse Reactions and Frequencies

Adverse reactions are grouped by the frequency reported in clinical data, ranging from Most Common to Rare events.

Classification (Examples) Body System (SOC) Involved
Most Common (e.g., Headache, Diarrhea, Rash, Nausea) Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders
Uncommon (e.g., Leukopenia, Thrombocytopenia) Blood and Lymphatic System Disorders
Rare (e.g., Convulsions) Nervous System Disorders

Serious adverse reactions are specifically highlighted in regulatory labeling due to their clinical importance. These include severe hypersensitivity reactions (such as anaphylaxis), serious cutaneous adverse reactions (SCAR) like Stevens-Johnson syndrome, and adverse Central Nervous System (CNS) effects such as seizures.


Population-Specific Safety Considerations

The official labeling notes specific safety considerations for certain patient populations:

  • Renal Impairment: Patients with reduced kidney function may require specific dose adjustments and monitoring, as they have an increased risk of certain adverse hematological events.
  • Older Adults: Dose adjustment may be necessary due to the higher likelihood of age-related decrease in renal function.
  • Contraindications: The medicine is formally contraindicated for use in individuals with known severe hypersensitivity to Meropenem, other carbapenem antibiotics, or any severe allergic reaction to a beta-lactam antibacterial agent (e.g., penicillins or cephalosporins).

Additionally, co-administration with valproic acid is not recommended due to the potential safety consequence of a reduced valproic acid serum concentration, which increases the risk of breakthrough seizures.

Overdose and Emergency Response

Merimac Overdose and when to seek help

The official regulatory documents define the Merimac (Meropenem) overdose profile by the potential for severe, dose-related toxicological effects affecting the nervous system. Accidental overdosage may present primarily with signs of neurotoxicity and adverse Central Nervous System (CNS) experiences, including seizures.

The risk of these severe CNS manifestations is directly associated with elevated plasma concentrations and drug accumulation. A critical population-specific consideration exists for patients with renal impairment, defined as a creatinine clearance of 50 mL/min or less. In these individuals, the drug is not adequately cleared, increasing the likelihood of accumulation and subsequent toxicity. Warnings also address the need to prevent unintentional overdose in pediatric patients requiring partial dosing.

In the event of accidental overdosage, regulatory guidance mandates that patients must contact a doctor or the nearest hospital straight away to seek immediate medical attention. Management for overdosage is defined as symptomatic and supportive treatment. No specific antidote for Merimac overdose is known. However, Meropenem is effectively cleared from the body by procedural steps such as haemodialysis and haemofiltration, which are measures defined to reduce excessive systemic exposure.

Therapeutic Uses of Merimac

Merimac is indicated as a therapeutic option to support the management of specific bacterial infections in adults and children. It may be used to address complex infections affecting the skin, lungs (such as pneumonia), and the abdominal area. It is also considered for managing meningitis, which is an infection of the membranes surrounding the brain and spinal cord.

The benefit of Merimac is derived from its role in supporting the body's response against susceptible bacteria to promote recovery. The treatment is primarily reserved for scenarios where other therapeutic choices may not be suitable or effective. The specific type of infection, the patient’s overall health, and the response to therapy all guide its appropriate use.


Quick Fact: Supports the management of Severe Bacterial Infections

Regulatory References

  1. NIH MedlinePlus Drug Information on Meropenem

Eligibility and Restrictions for Use

Merimac eligibility is strictly defined by regulatory documents, establishing clear criteria for use and non-eligibility.

Populations Who Must Not Use Merimac

The medicine is contraindicated and must not be used by patients who have a known hypersensitivity (allergy) to Merimac, any carbapenem antibiotic, or a history of a severe allergic reaction to any other beta-lactam antibacterial agent (such as penicillins).

Age and Condition Restrictions

Use is established for adults and pediatric patients 3 months of age and older. The safety and efficacy are not established for children under 3 months of age, and its use in this population is therefore not recommended.

Patients with impaired renal function (creatinine clearance of 50 mL/min or less) require a mandatory dosage adjustment, a specific restriction outlined in official labeling. Use is also conditional for pregnant and lactating women; human data is insufficient for pregnancy risk, and the medicine is known to be excreted in human milk. Patients with a history of CNS disorders, such as seizures, must be administered the medicine with caution.

What should I know about interactions with other medicines?

The official interaction profile for Merimac is structured around documented pharmacokinetic relationships with specific medicinal products.

Documented Pharmacokinetic Interactions

Restriction on Co-administration The co-administration of Merimac with valproic acid, divalproex sodium, or sodium valproate is officially not recommended by regulatory agencies. This strict restriction is due to a rapid and significant pharmacokinetic interaction that results in a substantial reduction in the serum concentrations of the valproate agent, an outcome explicitly noted in the regulatory labeling.

Interactions Affecting Clearance A clear interaction is documented with Probenecid, an agent that influences renal elimination. Probenecid inhibits the active renal tubular secretion of Merimac. This pharmacokinetic mechanism leads to a quantifiable increase in the plasma concentration and elimination half-life of Merimac.

Interactions with Other Substances Merimac is also noted in official regulatory documentation for its potential to interact with certain oral hormonal contraceptives. The therapeutic effectiveness of these agents may be decreased due to the documented effect of broad-spectrum antibiotics, including Merimac, on the intestinal flora. No specific timing requirements or population-dependent interaction considerations are mandated in the official prescribing information for any co-administered substance.

Mechanism of Action

How Merimac Works

Merimac (Meropenem) acts within the domain of bacterial structural synthesis by targeting a family of enzymes known as Penicillin-Binding Proteins (PBPs). The drug functions as an irreversible inhibitor, binding covalently to the PBP active site to permanently halt its function, which immediately stops the essential process of peptidoglycan cross-linking. This mechanism is focused on altering the pathogen's core structural integrity.

The irreversible blockade of PBPs triggers a destructive mechanistic cascade resulting in a bactericidal effect. The ensuing structural instability activates the bacterial cell's own internal autolytic enzymes. This leads to the rapid lysis (rupture) of the bacterial cell wall, which is the key physiological consequence, resulting in the rupture and death of the bacterial cell.

The mechanism's activity is influenced by mechanistic counter-pathways that reduce the drug's concentration at the target site. This occurs primarily when bacteria produce carbapenemase enzymes which chemically hydrolyze the drug before it reaches the PBPs, or when the bacteria actively reduce drug uptake through porin changes or efflux pumps, thereby interrupting the PBP inhibition cascade.

Dosage and Administration Information

Merimac is reserved exclusively for intravenous (IV) administration and is typically managed in a controlled clinical environment. It is supplied as a sterile powder for injection that a healthcare professional must reconstitute before use. The preparation process involves mixing the powder with a suitable diluent, such as Sterile Water for Injection, and then further diluting it, often with 0.9% Sodium Chloride solution, before it is administered.

The medicine can be given either as a rapid IV bolus injection over three to five minutes or as a standard IV infusion lasting 15 to 30 minutes. For most common usage patterns, Merimac is administered on a fixed schedule, with dosing repeated every 8 hours. The duration of this course of therapy is not fixed and depends on the specific infection being addressed.

Standard adult dosing ranges from 500 mg to 2 g per administration. For children aged three months and older, the dose is calculated based on the child’s body weight in kilograms. A critical procedural instruction requires that the dose or frequency be adjusted for adult patients who have impaired kidney function. Conversely, no specific dose adjustment is considered necessary for patients with impaired hepatic function, provided their kidney function is normal. Before administration, the final solution must be visually inspected to ensure it is clear and free of particulate matter.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Merimac


Evidence for Use in Episodic Conditions

Research examined Merimac in populations with conditions characterized by fluctuating or episodic manifestations. Researchers primarily used short-term, randomized studies designed to compare different groups over defined time intervals. These studies explored outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. The populations included in this research consisted primarily of adults experiencing mild to moderate symptom activity. The findings from these studies describe patterns observed in the specific populations that were evaluated. However, evidence is limited regarding the long-term patterns associated with Merimac, as follow-up durations were limited.


Evidence for Use During Heightened Symptom Activity

Research explored Merimac in populations with conditions involving periods of heightened symptoms, using a mix of observational studies and smaller, exploratory trials. This research primarily examined measurements of outcomes capturing phases of heightened symptom activity and outcomes linked to inflammatory or irritative states. Data from these scenarios indicate patterns related to measured physiological strain during episodes of symptom activity. Limited information is available to draw conclusions across diverse groups, as comparative evidence is lacking, and the findings across different studies for this indication were mixed.


Long-term Studies and Follow-up

Research has explored how the patterns observed in short-term studies continue, but long-term effects are not fully established. Most available data for Merimac is derived from short-term trials, where follow-up durations were limited. Because long-term outcomes are not well characterized, the data for extended periods remain insufficient to assess the consistency of observed patterns or the monitoring of systemic or functional imbalance. Further research may help address questions regarding these extended time frames.


What is Still Uncertain About Merimac

The current evidence base for Merimac describes several limitations. Evidence quality varies across studies, and the studies often included sample sizes that were modest. Research findings describe group patterns, not personal outcomes, and that the study results are based on the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Merimac (FAQ)


Q: Is Merimac the same type of medicine as [similar common drug name]?

Merimac is consistently categorized in official documents as a carbapenem antibiotic. This classification places it within a specific family of potent antibacterials typically reserved for treating severe bacterial infections. This description defines the drug's mechanism of action and its general purpose, as described in official medical texts.


Q: How quickly can I expect Merimac to start working?

The medicine works through a rapid, bactericidal mechanism that results in the rupture and death of bacterial cells. Official documents do not specify a time frame for when a patient can expect to feel better, as the time to clinical response is based on the specific infection being treated.


Q: What is the typical length of time people take Merimac for?

The duration of therapy with Merimac is not fixed and is determined by the specific type and severity of the infection being addressed. For many common uses, the course of therapy often lasts several days to two weeks. The final duration of use is determined based on individual clinical factors.


Q: Is it normal to feel tired when first taking Merimac?

Regulatory documents list potential adverse events affecting the nervous system, such as headache and seizures, and general conditions like nausea and weakness. While tiredness is not explicitly listed, these related effects may potentially contribute to feelings of fatigue.


Q: What is the difference between Merimac and a supplement for the same condition?

Merimac is a synthetic, prescription-only antibiotic (a carbapenem) used to treat severe bacterial infections, placing it under strict regulatory control. Dietary supplements are not regulated or approved by health authorities for the treatment of severe bacterial infections.


Q: Do studies suggest Merimac is well-tolerated?

Clinical data indicates that Merimac is generally well-tolerated in the patient populations studied. The most frequently reported adverse events often involve gastrointestinal issues, rash, or irritation at the injection site.


Q: Can Merimac affect my ability to drive or operate machinery?

Official regulatory labeling includes a warning about the potential for neuromotor impairment. This means that adverse events like seizures or delirium could potentially interfere with mental alertness and motor function.


Q: Why do some people say Merimac didn't work for them?

The drug's effectiveness can be affected by bacterial resistance pathways. These include the production of enzymes (carbapenemases) or changes in the bacteria’s cell wall that prevent the medicine from reaching its target.


Q: Do clinical trials of Merimac include diverse populations?

Research summaries acknowledge that limited information is available to draw conclusions about the drug's patterns of use across highly diverse patient groups. The current findings reflect the specific populations that were evaluated in the clinical studies.


Q: Can Merimac cause changes in mood or sleep patterns?

Adverse events reported to the nervous system include more serious events such as delirium, confusion, and psychosis. These severe Central Nervous System (CNS) effects, as described in the labeling, may be associated with changes in mood or sleep patterns.


Q: Why is the official dosage range for Merimac so wide?

The dosage is highly variable because its variation is based on individual clinical factors. It depends on the type and severity of the infection being treated, the specific organism causing the infection, and the patient's kidney function.


Q: Where can I find the official patient information leaflet for Merimac?

Official patient information, sometimes called the Patient Information Leaflet or Patient Medication Information, is included within the comprehensive regulatory documents. These documents, such as the FDA label or Product Monograph, are provided by the manufacturer.


Q: Can Merimac be taken with or without food?

Merimac is administered exclusively by intravenous (IV) injection or infusion in a controlled clinical setting. Since the medicine is delivered directly into the bloodstream, taking it with or without food is not a relevant factor for administration.


Q: Does the effectiveness of Merimac vary based on age or gender?

Dosing is specifically adjusted for certain age groups and patients with impaired kidney function. Official documents do not typically specify differential effectiveness based on gender.


Q: Are there specific warnings about taking Merimac with other medications for mental health?

Official warnings specifically highlight the co-administration with valproic acid, divalproex sodium, or sodium valproate. This is because Merimac can significantly reduce the concentration of the valproate agent in the body.


Q: Does Merimac have a generic version available?

Yes, Merimac is the brand name for the active ingredient meropenem. Generic versions of meropenem have been approved and are available in many areas, according to regulatory authorities.


Q: Are there any common foods or drinks to avoid while taking Merimac?

Merimac is formulated with sodium as a component. This amount of sodium is a factor that may require consideration for patients with specific health conditions that require sodium restriction (such as heart failure or hypertension).


Q: What if I forget to take a dose of Merimac?

General guidance for missed antibiotic doses referenced in regulatory guidance generally indicates a course of action to be followed. This typically involves taking the dose as soon as it is remembered, unless it is almost time for the next scheduled dose, in which case the missed dose is typically skipped.


Q: What happens if I stop taking Merimac suddenly?

Antibiotics are generally required to be used for the full course of therapy prescribed. This is necessary to ensure the infection is completely treated and to reduce the risk of developing drug-resistant bacteria.


Q: Is there a risk of dependence or addiction with Merimac?

Official documents do not classify Merimac as a Controlled Substance or a scheduled drug. Regulatory authorities have not identified a known potential for dependence or addiction with this medicine.


Q: Does Merimac interact with alcohol?

Official regulatory documents do not list a specific pharmacokinetic interaction with alcohol. However, like many medicines, it is generally noted that avoiding alcohol may help to prevent common side effects such as dizziness or stomach upset.


Q: Does Merimac interact with common over-the-counter pain relievers?

Regulatory reviews generally report no clinically significant interactions between Merimac and common over-the-counter pain relievers like acetaminophen (paracetamol).


Q: Does Merimac require regular blood tests or monitoring?

Due to potential effects on the blood, liver, and kidneys, official product information notes that monitoring of these functions may be necessary. Monitoring is especially noted for patients with pre-existing conditions.


Q: Does Merimac interact with herbal supplements like St. John's Wort?

It is generally noted in official information that disclosure of all other medications, including herbal supplements, is important. The full interaction profile with every non-prescription product is not always fully established in regulatory documents.


Q: How long does Merimac stay in your system after stopping?

The duration the medicine remains in the body is determined by its elimination half-life. This half-life is typically less than two hours for meropenem in adults with normal kidney function.


Q: What happens if I accidentally take too much Merimac?

The official label includes information on Overdosage. It notes that in the event of an accidental overdose, the medicine can be removed from the body by hemodialysis in patients with impaired renal function.


Q: Why is Merimac sometimes prescribed for uses not listed as the primary one?

The official documents strictly define the approved conditions for which the medicine has demonstrated safety and effectiveness. Regulatory agencies do not discuss or comment on other potential uses beyond the scope of approved indications.


Q: Is Merimac a Schedule drug or a Controlled Substance?

Merimac is categorized as a prescription-only medicine. It is not classified as a Controlled Substance (Schedule I-V) by national regulatory authorities.


Q: What does the term 'off-label use' mean in the context of Merimac?

The term refers to the use of a medicine for an unapproved indication, in an unapproved age group, at an unapproved dosage, or by an unapproved route of administration, according to official medical definitions.

How should Merimac be stored and disposed of?

How to Store and Dispose of Merimac?

Merimac must be stored and handled according to the official requirements detailed in its regulatory labeling to maintain the product's quality and safety profile.

Storage and Handling Profile

Requirement Official Regulatory Mandate
Container Integrity The container closure system must provide adequate protection from external factors, such as light and moisture, to ensure the drug's safety, identity, strength, and purity.
In-Use Stability If required, adhere strictly to any officially defined stability periods (e.g., maximum use duration after reconstitution) to ensure the drug remains effective and safe.
Protection The container materials must not react with, absorb, or release substances that would alter the drug's quality beyond specified limits.

Disposal Instructions

Proper disposal is essential to prevent accidental exposure. Official labeling mandates that Merimac, including any used delivery systems or remnants, must be discarded in a manner that minimizes the risk of harm to children, adults, and pets. Disposal must be carried out in accordance with all local, regional, and national regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Merimac found in:

A-Z Index: